- Home
- RMAX vs ENTA Comparison
RMAX vs ENTA Comparison
Compare RMAX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- ENTA
- Stock Information
- Founded
- RMAX 1973
- ENTA 1995
- Country
- RMAX United States
- ENTA United States
- Employees
- RMAX N/A
- ENTA N/A
- Industry
- RMAX Real Estate
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- RMAX Finance
- ENTA Health Care
- Exchange
- RMAX Nasdaq
- ENTA Nasdaq
- Market Cap
- RMAX 161.9M
- ENTA 154.0M
- IPO Year
- RMAX 2013
- ENTA 2013
- Fundamental
- Price
- RMAX $7.29
- ENTA $5.10
- Analyst Decision
- RMAX Hold
- ENTA Buy
- Analyst Count
- RMAX 1
- ENTA 4
- Target Price
- RMAX $10.50
- ENTA $17.25
- AVG Volume (30 Days)
- RMAX 151.0K
- ENTA 266.6K
- Earning Date
- RMAX 05-01-2025
- ENTA 05-05-2025
- Dividend Yield
- RMAX N/A
- ENTA N/A
- EPS Growth
- RMAX N/A
- ENTA N/A
- EPS
- RMAX 0.37
- ENTA N/A
- Revenue
- RMAX $307,685,000.00
- ENTA $66,590,999.00
- Revenue This Year
- RMAX N/A
- ENTA N/A
- Revenue Next Year
- RMAX $1.25
- ENTA N/A
- P/E Ratio
- RMAX $19.70
- ENTA N/A
- Revenue Growth
- RMAX N/A
- ENTA N/A
- 52 Week Low
- RMAX $6.90
- ENTA $4.09
- 52 Week High
- RMAX $14.31
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- RMAX 34.80
- ENTA 43.45
- Support Level
- RMAX $7.22
- ENTA $4.55
- Resistance Level
- RMAX $7.87
- ENTA $5.29
- Average True Range (ATR)
- RMAX 0.44
- ENTA 0.47
- MACD
- RMAX -0.03
- ENTA 0.06
- Stochastic Oscillator
- RMAX 24.53
- ENTA 63.96
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.